Alaabta

1. Si loo baaro in adenosine diphosphate (ADP) -derived adenosine laga yaabo inuu joojiyo isu-ururinta platelet, gaar ahaan joogitaanka P2Y₁₁ antagonist, halkaas oo saamaynta ADP ee P2Y₁₁ receptor laga hortagi lahaa. Isku-darka Platelet ayaa la qiyaasay iyada oo laga jawaabayo activator receptor thrombin peptide by platelet tirinta ee plazma-hodan ku ah platelet (PRP) iyo dhiiga oo dhan joogitaanka ADP iyo P2Y₁₂ antagonists cangrelor, prasugrel firfircoon metabolite, iyo ticagrelor.Marka uu joogo P2Y₁₁ antagonist, preincubation of PRP oo leh ADP la hakiyay isku darka;Saamayntan waxaa baabi'iyay adenosine deaminase.Ma jiro xannibaad isku-ururin ah oo ku dhacay dhiigga oo dhan marka laga reebo marka dipyridamole lagu daray si loo joojiyo qaadashada adenosine ee erythrocytes.Saamaynta ADP ee PRP iyo dhiigga oo dhan ayaa lagu soo koobay iyadoo la adeegsanayo adenosine waxayna si toos ah ula xiriirtay isbeddelada cAMP (oo lagu qiimeeyay fosfooraska fosfooprotein-kicin ee vasodilator).Natiijooyinka oo dhami waxay ahaayeen isku mid iyadoon loo eegin P2Y₁₁ ant agonist la isticmaalay.ADP waxay joojisaa isu geynta platelet marka uu jiro P2Y₁₁ antagonist iyada oo loo beddelayo adenosine.Xannibaadu waxay ku dhacdaa PRP laakiin maaha dhiiga oo dhan marka laga reebo marka adenosine qaadashada la joojiyo.Ma jiro mid ka mid ah P2Y₁₁ antagonists oo la darsay oo ku celceliyay saamaynta dipyridamole ee tijaabooyinka la sameeyay.

2.ADP waxaa loo tixgeliyaa agonist daciif ah oo tabar-daran sababtoo ah jawaabaha isku-darka xaddidan ee ay ku keento vitro-yada jir ahaaneed ee Ca (2+) [(Ca (2+)) (o) ].Hoos u dhigista [Ca(2+)] (o) waxay si aan kala sooc lahayn u wanaajisaa isu-ururinta ADP-kicisay, saamayn loo aaneeyay soosaarka thromboxane A(2) oo la xoojiyay.Daraasadani waxay eegtay doorka ectonucleotidases ee [Ca (2+)] (o) -ku-tiirsanaanta firfircoonida platelet.Hoos u dhigida [Ca(2+)] (o) min millimolar ilaa heerar micromolar ah ayaa loo beddelay ADP (10 μmol/l) -isku-darka platelet-ka ee la soo kiciyay ee ku meel gaadhka ah ilaa jawaab joogta ah oo ku jirta balaasmaha qani ku ah platelet iyo ganaax la dhaqay.Joojinta soo saarista thromboxane A(2) ee leh aspirin wax saamayn ah kuma yeelan tan [Ca(2+)] (o) -ku-tiirsanaanta.Ka-hortagga xaalufka ADP wuxuu baabi'iyay faraqa u dhexeeya hoose iyo physiological [Ca(2+)] (o) taasoo keentay isu-ururin adag oo joogto ah labada xaaladood.Cabbiraadaha ADP ee ka baxsan unugyada ayaa muujiyay hoos u dhac ku yimaada labadaba balaasmaha iyo apyrase-ka kooban g saline ee micromolar marka la barbar dhigo millimolar [Ca (2+)] (o) .Sidii hore loo sheegay, jiilka thromboxane A (2) ayaa la wanaajiyey [Ca (2+)] (o), si kastaba ha ahaatee tani waxay ka madax banaan tahay dhaqdhaqaaqa ectonucleotidase Isugeynta ADP-kicinta joogtada ah, oo leh door yar oo loogu talagalay P2Y(1) .Gebogebadii, Ca (2+) -ku-tiirsanaanta ectonucleotidase-ku-tiirsanaanta ayaa ah arrin weyn oo go'aamisa xadka isku-darka platelet ilaa ADP waana in lagu xakameeyaa daraasadaha firfircoonida soo-dhoweynta P2Y.